Journal article icon

Journal article

How should we manage women with unexplained chronic pelvic pain in light of uncertainty about the effectiveness of gabapentin?

Abstract:
Chronic pelvic pain affects 2.1% to 24% of the global female population, and up to half of the affected women have no obvious pathology. The neuromodulator gabapentin can be used to modulate pain, but the evidence for its effectiveness and safety is limited, as discussed by Andrew Horne and colleagues in a related article (doi:10.1136/bmj.j3520). Here, James Duffy explores how we should manage women with unexplained chronic pain in light of this uncertainty.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/bmj.j3624

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author
Publisher:
BMJ Publishing Group
Journal:
BMJ More from this journal
Publication date:
2017-09-01
Acceptance date:
2017-09-01
DOI:
EISSN:
1756-1833
ISSN:
0959-8138
Pubs id:
pubs:730754
UUID:
uuid:07203339-e689-4692-b278-4a9b049af86f
Local pid:
pubs:730754
Source identifiers:
730754
Deposit date:
2018-01-07

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP